Akebia Therapeutics Q1 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $32.607M Miss $46.087M Estimate
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics reported Q1 2024 earnings with a GAAP EPS of $(0.09), missing the $(0.08) estimate, and sales of $32.607M, falling short of the $46.087M estimate.

May 09, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Akebia Therapeutics missed Q1 2024 earnings and sales estimates, with a GAAP EPS of $(0.09) and sales of $32.607M.
Missing both earnings and sales estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. The significant miss in sales estimates by 29.25% and the earnings miss by 12.5% are likely to be viewed unfavorably by the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100